KineMed and Bayer Healthcare AG Enter Collaboration to Discover New Therapeutic Applications for Drug Candidates
EMERYVILLE, Calif., February 06, 2007 /PRNewswire/ -- KineMed, Inc., a pathway-based drug discovery and development company, and Bayer Healthcare AG announced today that they have signed an agreement to discover new therapeutic applications. Under the terms of the agreement, KineMed will identify new therapeutic utility by applying its proprietary translational medicine technologies (AquaTag(TM) and KineMarker(TM)). Once a disease target is established for a selected drug candidate, KineMed and Bayer Healthcare AG will jointly determine the best development and commercialization path.
David Fineman, President and CEO of KineMed, commented, "The collaboration with Bayer Healthcare AG is an important opportunity for us to discover new indications for promising compounds and to work with Bayer Healthcare AG to pursue clinical development. This is in fact the third indications discovery deal we have announced in the past year, each of which gives us the option to move into more advanced product development."
Mr. Fineman continued, "In addition to signing a partnership with Bayer Healthcare AG, we have over two dozen early-stage partnered collaborations that further validate our broad platform in translational medicine. In one program, we recently reported the advancement of the relationship to support clinical studies. Our goal over the next 12 months is to demonstrate further acceleration of these programs and to report dose-response and efficacy findings in Phase I, key evidence of our ability to de-risk clinical development."
About KineMed, Inc.
KineMed, Inc. ("KineMed" or the "Company") is a drug discovery and development company employing its proprietary translational medicine technology (AquaTag(TM) and KineMarker(TM)) to both identify active drug candidates preclinically and confirm their therapeutic activity and dose response in first-in-man studies. The Company is working to develop drugs both on its own and with pharmaceutical collaborators in therapeutic focus areas where it can demonstrate functional modulation of specific biological pathways that mediate disease.
KineMed's technology expedites the drug development process and provides real-time insight into conditions including metabolic disorders, cancer, and diseases of inflammation and neurodegeneration.
For further information about KineMed, please visit: http://www.kinemed.com/
CONTACT: Brent Vaughan, Chief Business Officer of KineMed, Inc.,+1-510-655-6525, ext. 110; or Media: Justin Jackson of Burns McClellan,+1-212-213-0006, , for KineMed, Inc. email@example.com
Web site: http://www.kinemed.com/
Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company
Posted: February 2007